Back to Search
Start Over
FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia.
- Source :
-
Cytokine . Aug2019, Vol. 120, p85-87. 3p. - Publication Year :
- 2019
-
Abstract
- • Only prospective series looking at FLT3L concentrations impact after allo-HSCT. • Endogenous FLT3L concentration is not a prognostic marker in this setting. • FLT3L concentration could be monitored only during induction of AML. This study was designed to assess the impact on outcomes of early soluble Fms-like tyrosine kinase 3 ligand concentrations (sFLc) in patients receiving an allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This was a prospective monocentric study including all allo-HSCT patients included in the previous FLAM/FLAL study (Peterlin et al., 2019). Blood samples collected before the start of conditioning then post-transplant were frozen, stored and tested by ELISA. The parameters considered were hematopoietic recoveries, Leukemia Free Survival and Overall Survival, acute and chronic GVHD, grade 3 or 4 acute and/or extensive chronic GVHD-free and relapse-free survival (GRFS). Forty-one patients were included, a total of 179 samples were assayed for sFLc. There was no impact of sFLc levels (<=median vs> median) on acute and chronic GVHD incidences, LFS, OS nor GRFS. At variance with induction results for AML (Peterlin et al., 2019) endogenous sFLc do not appear to be a prognostic marker at the time of or after allo-HSCT. Even though the results are negatives, this is, to the best of our knowledge, the only prospective series specifically addressing the question of sFLc impact after allo-HSCT in acute leukemias. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10434666
- Volume :
- 120
- Database :
- Academic Search Index
- Journal :
- Cytokine
- Publication Type :
- Academic Journal
- Accession number :
- 136783680
- Full Text :
- https://doi.org/10.1016/j.cyto.2019.04.015